206 related articles for article (PubMed ID: 37418798)
21. Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
Abdalla N; Piorkowski R; Bachanek M; Stanirowski P; Cendrowski K; Sawicki W
Dis Markers; 2018; 2018():5289804. PubMed ID: 29849823
[TBL] [Abstract][Full Text] [Related]
22. The use of sonographic subjective tumor assessment, IOTA logistic regression model 1, IOTA Simple Rules and GI-RADS system in the preoperative prediction of malignancy in women with adnexal masses.
Koneczny J; Czekierdowski A; Florczak M; Poziemski P; Stachowicz N; Borowski D
Ginekol Pol; 2017; 88(12):647-653. PubMed ID: 29303221
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
24. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
25. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnexal masses and retrospective assessment of alternative two-step strategy using simple-rules risk.
Hidalgo JJ; Ros F; Aubá M; Errasti T; Olartecoechea B; Ruiz-Zambrana Á; Alcázar JL
Ultrasound Obstet Gynecol; 2019 May; 53(5):693-700. PubMed ID: 30353585
[TBL] [Abstract][Full Text] [Related]
26. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Braicu EI; Krause CL; Torsten U; Mecke H; Richter R; Hellmeyer L; Lanowska M; Müller B; Koch E; Boenneß-Zaloum J; Ames K; Chekerov R; Hasenbein K; Zimmermann M; Mangler M; Chen F; Tauber R; Sehouli J
BMC Cancer; 2022 Jul; 22(1):831. PubMed ID: 35907794
[TBL] [Abstract][Full Text] [Related]
27. External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups.
Timmerman S; Valentin L; Ceusters J; Testa AC; Landolfo C; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Kaijser J; Scambia G; Andreotti R; Timmerman D; Bourne T; Van Calster B; Froyman W
JAMA Oncol; 2023 Feb; 9(2):225-233. PubMed ID: 36520422
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound examination, MRI, or ROMA for discriminating between inconclusive adnexal masses as determined by IOTA Simple Rules: a prospective study.
Chacon E; Arraiza M; Manzour N; Benito A; Mínguez JÁ; Vázquez-Vicente D; Castellanos T; Chiva L; Alcazar JL
Int J Gynecol Cancer; 2023 Jun; 33(6):951-956. PubMed ID: 37055169
[TBL] [Abstract][Full Text] [Related]
29. Comparison of International Ovarian Tumor Analysis ADNEX model and Ovarian-Adnexal Reporting and Data System with final histological diagnosis in adnexal masses: a retrospective study.
Filiz AA; Kahyaoglu S; Atalay CR
Obstet Gynecol Sci; 2024 Jan; 67(1):86-93. PubMed ID: 37822234
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior doctors.
Guo Y; Zhao B; Zhou S; Wen L; Liu J; Fu Y; Xu F; Liu M
Ultrasonography; 2022 Jul; 41(3):511-518. PubMed ID: 35196832
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer.
Luo HJ; Hu ZD; Cui M; Zhang XF; Tian WY; Ma CQ; Ren YN; Dong ZL
J Obstet Gynaecol Res; 2023 Mar; 49(3):998-1006. PubMed ID: 36609691
[TBL] [Abstract][Full Text] [Related]
33. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
34. Prospective comparative trial comparing O-RADS, IOTA ADNEX model, and RMI score for preoperative evaluation of adnexal masses for prediction of ovarian cancer.
Poonyakanok V; Tanmahasamut P; Jaishuen A
J Obstet Gynaecol Res; 2023 May; 49(5):1412-1417. PubMed ID: 36895122
[TBL] [Abstract][Full Text] [Related]
35. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
36. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
[TBL] [Abstract][Full Text] [Related]
37. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
[TBL] [Abstract][Full Text] [Related]
38. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
[TBL] [Abstract][Full Text] [Related]
39. Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses.
Di Legge A; Testa AC; Ameye L; Van Calster B; Lissoni AA; Leone FP; Savelli L; Franchi D; Czekierdowski A; Trio D; Van Holsbeke C; Ferrazzi E; Scambia G; Timmerman D; Valentin L
Ultrasound Obstet Gynecol; 2012 Sep; 40(3):345-54. PubMed ID: 22611001
[TBL] [Abstract][Full Text] [Related]
40. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX: a Portuguese multicenter study.
Borges AL; Brito M; Ambrósio P; Condeço R; Pinto P; Ambrósio B; Mahomed F; Gama JMR; Bernardo MJ; Gouveia AI; Djokovic D
Ultrasound Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38477149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
